Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4116-4123

  Walsh, Thomas J ^a,b   Driscoll, Timothy ^c   Milligan, Peter A ^d   Wood, Nolan D ^e   Schlamm, Haran ^d,e   Groll, Andreas H ^f   Jafri, Hasan ^g   Arrieta, Antonio C ^h   Klein, Nigel J ⁱ   Lutsar, Irja ^d,j  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e PFIZER INC   (United States)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF TARTU   (Estonia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; VORICONAZOLE;

ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; COUGHING; DETERIORATION; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EPISTAXIS; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GROUPS BY AGE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; MALE; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; OPEN STUDY; PERICARDIAL EFFUSION; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RASH; RHINITIS; SCHOOL CHILD; SIDE EFFECT; VOMITING;

ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MYCOSES; PYRIMIDINES; TRIAZOLES;

EID: 77957360800     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00896-10     Document Type: Article

References (29)

1. Andes, D., A. Pascual, and O. Marchetti. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34.
2. Boucher, H. W., A. H. Groll, C. C. Chiou, and T. J. Walsh. 2004. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64:1997-2020.
3. Burgos, A., T. E. Zaoutis, C. C. Dvorak, J. A. Hoffman, K. M. Knapp, J. J. Nania, P. Prasad, W. J. Steinbach. 2008. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121:e1286-e1294.
4. Denning, D. W., and C. E. Griffiths. 2001. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin. Exp. Dermatol. 26:648-653.
5. Ghannoum, M. A., and D. M. Kuhn. 2002. Voriconazole - better chances for patients with invasive mycoses. Eur. J. Med. Res. 7:242-256.
6. Ginsberg, G., D. Hattis, B. Sonawane, A. Russ, P. Banati, M. Kozlak, S. Smolenski, and R. Goble. 2002. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 66:185-200.
7. Goldstein, J. A., and S. M. F. de Morais. 1994. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
8. Groll, A. H., M. Kurz, and W. Schneider. 1999. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 42:431-442.
9. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 8:347:408-415.
10. Hilliard, T., S. Edwards, R. Buchdahl, J. Francis, M. Rosenthal, I. Balfour-Lynn, A. Bush, and J. Davies. 2005. Voriconazole therapy in children with cystic fibrosis. J. Cystic Fibrosis 4:215-220.
11. Hovi, L., U. M. Saarinen-Pihkala, K. Vettenranta, and H. Saxen. 2000. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant. 26:999-1004.
12. Hyland, R., B. C. Jones, and D. A. Smith. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-547.
13. Karlsson, M. O., I. Lutsar, and P. A. Milligan. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53:935-944.
14. Mouas, H., I. Lutsar, B. Dupont, O. Fain, R. Herbrecht, F. X. Lescure, and O. Lortholary. 2005. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Voriconazole/Bone Invasive Aspergillosis Study Group. Clin. Infect. Dis. 40:1141-1147.
15. Neely, M., T. Rushing, A. Kovacs, R. Jelliffe, and J. Hoffman. 2010. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50:27-36.
16. Pfizer Inc. 2006. Voriconazole package insert. Pfizer Inc., New York, NY.
17. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
18. Purkins, L., N. Wood, K. Greenhalgh, M. D. Eve, S. D. Oliver, and D. Nichols. 2003. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56(Suppl. 1):2-9.
19. Rosen, G. P., K. Nielsen, S. Glenn, J. Abelson, J. Deville, and T. B. Moore. 2005. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J. Pediatr. Hematol. Oncol. 27:135-140.
20. Schwartz, S., M. Ruhnke, P. Ribaud, L. Corey, T. Driscoll, O. A. Cornely, U. Schuler, I. Lutsar, P. Troke, and E. Thiel. 2005. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106:2641-2645. (Pubitemid 41510735)
21. Steinbach, W. J., and T. J. Walsh. 2006. Mycoses in pediatric patients. Infect. Dis. Clin. North Am. 20:663-678.
22. Stopher, D. A., and R. Gage. 1997. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J. Chromatogr. B Biomed. Sci. Appl. 691:441-448.
23. Tan, K., N. Brayshaw, K. Tomaszewski, P. Troke, and N. Wood. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243.
24. Walsh, T. J., M. O. Karlsson, T. Driscoll, A. G. Arguedas, P. Adamson, X. Saez-Llorens, A. J. Vora, A. C. Arrieta, J. Blumer, I. Lutsar, P. Milligan, and N. Wood. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-2172.
25. Walsh, T. J., I. Lutsar, T. Driscoll, B. Dupont, M. Roden, P. Ghahramani, M. Hodges, A. H. Groll, and J. R. Perfect. 2002. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21:240-248.
26. Walsh, T. J., P. Pappas, D. J. Winston, H. M. Lazarus, F. Petersen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz, J. Lee, M. Schuster, A. Reboli, J. Wingard, C. Arndt, J. Reinhardt, S. Hadley, R. Finberg, M. Laverdiere, J. Perfect, G. Garber, G. Fioritoni, and E. Anaissie. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346:225-234.
27. Zaoutis, T. E., S. E. Coffin, J. H. Chu, K. Heydon, H. M. Greves, and T. J. Walsh. 2005. Risk factors for mortality in children with candidemia. Pediatr. Infect. Dis. 24:736-739.
28. Zaoutis, T. E., K. Heydon, J. H. Chu, T. J. Walsh, and W. J. Steinbach. 2006. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117:e711-e716.
29. Zonios, D. I., J. Gea-Banacloche, R. Childs, and J. E. Bennett. 2008. Hallucinations during voriconazole therapy. Clin. Infect. Dis. 47:e7-e10.